International Journal of Medicinal Mushrooms

ISSN for PRINT: 1521-9437

For Online Access

Best Paper Award Selection - Editorial Board Site

2002, Volume4

Issue 4

112 pages

Issue price - $128.00

Yihuai Gao
Institute of Food, Nutrition and Human Health, Massey University; Landcare Research, Private Bag 92170, Auckland, New Zealand

Shufeng Zhou
Division of Pharmacy, School of Life Sciences, Faculty of Science, Queensland University of Technology, Queensland 4001, Australia; and Department of Pharmacy, Faculty of Science, National University of Singapore, Singapore

Guoliang Chen
Division of Traditional Chinese Medicine, New Zealand Institute of Natural Medicines, Auckland, New Zealand

Xihu Dai
Department of Internal Medicine, Fuzhou General Hospital of Nanjing Military Region of the Peoples' Liberation Army, Fuzhou, R.P. China

Jingxian Ye
Department of Integrated Medicine. Hospital of Fujian University of Traditional Chinese Medicine, Fuzhou, R.P. China

He Gao
Division of Traditional Chinese Medicine, New Zealand Institute of Natural Medicines, Auckland, New Zealand

The polysaccharide fractions and triterpenes isolated from Ganoderma lucidum have shown protection effects on the liver in animal studies. This double-blind, randomised, and multicentered study aimed to evaluate the safety and effect of a G. lucidum extraction, Ganopoly, in chronic hepatitis B. Ninety patients with chronic hepatitis B, hepatitis В viral (HBV) DNA positivity, and aminotransferase elevation were included in this multicenter prospective randomized Phase I/II study. Patients were randomized to be given Ganopoly (n = 60) or placebo (n = 30) for 12 weeks, then followed up for 13 weeks. Effect of therapy on levels of HBV DNA and aminotransferase activities in serum and hepatitis В е antigen (HBeAg) status were investigated. There were 78 assessable patients who entered the trial for efficacy and safety; 13 of 52 (25%) patients receiving Ganopoly responded by reducing HBeAg and HBV DNA, compared to 1 of 26 (4%) in the control group (P < 0.05). Among those with serum aspartate aminotransferase (AST) values < 100 U/L (n = 29), 41% (12/29) responded, and among those with AST values > 100 U/L (n = 23), 65% (15/23) responded. Within the 6-month study period, 33% (17/ 52) of treated patients had normal aminotransferase (ALT) values, and 13% (7/52) had cleared hepatitis B surface antigen (HBsAg) from serum, whereas none of the controls had normal ALT values or had lost HBsAg. Eight of 60 patients in Ganopoly group and 4 of 30 in the controls were unable to be followed up due to loss or withdrawal. Our study indicates that Ganopoly is well tolerated and appears to be active against HBV in patients with chronic hepatitis B.

Download article, 7 pages

Article price - $35.00

<< Previous article   Next article >>